3 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.
3 citations
,
November 2023 in “BMC Public Health” In this study, EQ-5D-5L and SF-6DV2 showed suitable measurement properties in assessing health utility among Chinese university staff and students, though they reported differences in sensitivity and cannot be used interchangeably.
1 citations
,
July 2024 in “PharmacoEconomics - Open” This study indicates that the EQ-5D-5L may not effectively capture the burden of alopecia areata on patients' health-related quality of life, and suggests that alternative measures might better assess treatment benefits related to hair regrowth.
2 citations
,
March 2025 in “ESMO Open” In this extended follow-up of the PALOMA-2 trial, no significant differences in overall quality of life were observed between first-line treatments for metastatic breast cancer, but palbociclib plus letrozole showed some benefits regarding side-effects and hair loss.
128 citations
,
February 2016 in “British Journal of Dermatology” This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.